NeuroMetrix, Inc., a medical device company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders, such as those associated with carpal tunnel syndrome, lumbosacral disc disease, spinal stenosis, and diabetes. The company focuses on the diagnosis and treatment of neurological complications of diabetes, including diabetic peripheral neuropathy (DPN) and median neuropathy. Its marketed products include NC-stat DPNCheck, a device used to evaluate systemic neuropathies, such as DPN at the point-of-care; SENSUS pain therapy device, a transcutaneous electrical nerve stimulator used for chronic and intractable pain relief; and ADVANCE NCS/EMG system, a platform for the performance of traditional nerve conduction studies and invasive electromyography procedures for the assesment of CTS, low back and leg pain, and DPN, as well as consumables and accessories. The company is also developing SENTINEL device that provides sensory enhancement in the feet targeted at patients who have lost sensory perception in the lower extremities. NeuroMetrix, Inc. distributes its products directly through its direct sales force and independent sales representatives to physicians, clinics, hospitals, managed care organizations, retail health businesses, and independent distributors consisting of primary care, internal medicine, orthopedic and hand surgeons, pain medicine physicians, neurologists, physical medicine and rehabilitation, physicians, and neurosurgeons, as well as endocrinology and podiatry markets primarily in the United States, the United Kingdom, the Netherlands, and India. The company was founded in 1996 and is headquartered in Waltham, Massachusetts.